Article

Forbes on 2022-05-03 16:08

Biogen CEO Stepping Down After Struggles With Alzheimer’s Drug Aduhelm

The company said it will substantially eliminate the sales infrastructure related to Aduhelm, which is intended to provide savings of $1 billion ...

Cambridge

Michel Vounatsos

Related news

Biogen CEO: ‘Major bottleneck’ still limits Alzheimer’s drug Seattle Times
Massachusetts , Cambridge
Biogen to replace CEO after Alzheimer’s drug flops journalrecord.com
Europe , Wall Street , Massachusetts , Cambridge
Biogen seeks new chief, cuts Aduhelm spending Arkansas Online
Europe , Wall Street , Cambridge
Change at the top at Biogen after struggles with Aduhelm Seattle Times
Massachusetts
HBiogen Tumbles After Medicare Lays Out Aduhelm Coverage Plan hamodia.com
Cambridge , Lays-sur-le-Doubs
Biogen tumbles after Medicare lays out Aduhelm coverage plan Seattle Times
Cambridge
Biogen tumbles after Medicare lays out Aduhelm coverage plan - Wed, 12 Jan 2022 PST apnews.com
Cambridge
Biogen cuts Alzheimer’s drug price 50% months after approval Seattle Times
New York , Cambridge
Biogen cuts the price for its Alzheimer’s drug in half pressherald.com
Massachusetts , Cambridge , Japan
New Alzheimer’s treatment Aduhelm may be too costly for many seniors, deepening inequities Merced Sun-Star
Philadelphia , Cambridge
Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelm The New York Times
BBiogen Searches for New CEO in Wake of Struggles With Alzheimer's Drug 4 min read barrons.com
Biogen tabs veteran pharma leader Viehbacher as next CEO seattletimes.com
Cambridge , France
Biogen cuts the price tag on its Alzheimer’s drug in half journalrecord.com
Japan , Cambridge
Biogen plans to shut down its controversial Alzheimer’s drug Aduhelm Seattle Times
Japan
Biogen CEO scoops up $2.3M Back Bay condo bizjournals.com
Suffolk , Cambridge
HBiogen Cuts the Price Tag on its Alzheimer’s Drug in Half hamodia.com
Japan , Cambridge